Medication info
Actorin Tablets 30 mg (Pioglitazone Hydrochloride)

Actorin Tablets 30 mg (Pioglitazone Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Pioglitazone Hydrochloride›33.06mg / 1 tablet
Manufacturer / importer
Nexpharm Korea Co., Ltd.
Appearance
White to grayish-white round tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 202000624 · Approved 2020.02.04 · Insurance code 662504340

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
This medicine is administered orally once daily, regardless of meals. Diabetes management should be individualized for each patient. Ideally, response to treatment should be assessed by monitoring glycated hemoglobin (HbA1c), which is a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the past 2 ~ 3 months. Clinically, this medicine should be administered for an appropriate period to evaluate changes in glycated hemoglobin (at least 3 months), provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this medicine does not provide an adequate response, the dose may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea, with an initial dose of 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the dose of the sulfonylurea should be reduced. 2) Metformin: This medicine may be administered in combination with metformin, with an initial dose of 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted due to symptoms of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be continued when starting combination therapy with this medicine. However, if a patient receiving this medicine in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see the Precautions section, Patients with Renal Impairment). Treatment with this medicine should not be initiated if the patient has clinical evidence of active liver disease or increased serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT) at the start of treatment (see Adverse Reactions and the Precautions section, Effects on the Liver). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter. There are no data on administration of this medicine in combination with other thiazolidinediones.
Child dose
Under 18 years of age: Use is not recommended because there is no experience with its use.

Ingredients

Manufacturer
Nexpharm Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 Diabetes
View approved original text

This medication is mainly used as an adjunct to diet and exercise for blood sugar control in patients with type 2 diabetes. It can be administered alone or in combination with sulfonylureas, metformin, or insulin if blood sugar improvement is insufficient. Additionally, patients with type 2 diabetes require nutritional counseling along with weight loss and regular exercise, which are crucial not only for the initial treatment but also for maintaining drug efficacy. Therefore, this medication is effectively used for improving blood sugar control and managing diabetes.

How to take

Adult dose

This medicine is administered orally once daily, regardless of meals. Diabetes management should be individualized for each patient. Ideally, response to treatment should be assessed by monitoring glycated hemoglobin (HbA1c), which is a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the past 2 ~ 3 months. Clinically, this medicine should be administered for an appropriate period to evaluate changes in glycated hemoglobin (at least 3 months), provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this medicine does not provide an adequate response, the dose may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea, with an initial dose of 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the dose of the sulfonylurea should be reduced. 2) Metformin: This medicine may be administered in combination with metformin, with an initial dose of 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted due to symptoms of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be continued when starting combination therapy with this medicine. However, if a patient receiving this medicine in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see the Precautions section, Patients with Renal Impairment). Treatment with this medicine should not be initiated if the patient has clinical evidence of active liver disease or increased serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT) at the start of treatment (see Adverse Reactions and the Precautions section, Effects on the Liver). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter. There are no data on administration of this medicine in combination with other thiazolidinediones.

Child dose

Under 18 years of age: Use is not recommended because there is no experience with its use.

Precautions

This medication is used for the treatment of type 2 diabetes and needs insulin to lower blood sugar effectively. During the course of this medication, symptoms of heart failure may occur, such as sudden weight gain, shortness of breath, and swelling of the legs; if these symptoms arise, inform your doctor immediately. Patients with heart failure or a history of heart failure should not use this medication, nor should patients with active bladder cancer or a history of bladder cancer, or patients with severe liver or kidney dysfunction. Women who are pregnant or may become pregnant should not take this medication, and premenopausal women may have a higher risk of pregnancy due to ovulation while on this medication, so appropriate contraception is necessary. The risk of hypoglycemia may increase when this medication is used with other diabetes medications; hence, symptoms of hypoglycemia and management strategies should be well understood and dosage adjustments may be needed for other medications. Regular liver function tests should be conducted during treatment, and if symptoms of liver dysfunction (fatigue, loss of appetite, pain in the upper right abdomen, jaundice, etc.) occur, consult a doctor immediately. Swelling or weight gain may occur, and these symptoms can improve upon discontinuation of the medication. Long-term use of this medication may increase the risk of fractures, so special attention to bone health is especially necessary for women. If visible blood in the urine or urination disorders occur during treatment, inform your doctor immediately as it may indicate the possibility of bladder cancer. This medication is taken once daily, and if a dose is missed, do not double the dose the next day. Safety and efficacy have not been established in children and adolescents under 18 years of age. Elderly patients need special attention, and those over 75 years old should use the medication with increased caution. This medication may interact with other drugs; therefore, inform your doctor or pharmacist of any other medications being taken.

Side effects

Congestive heart failure, excessive and rapid weight change, shortness of breath, edema, fluid retention, swelling, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, back pain, dizziness, elevated serum creatine kinase, hypertension, heart failure, limb pain, back pain, chest pain, elevated serum creatinine, dizziness, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, dyspepsia, nausea, shortness of breath, itching, chest discomfort, tremor, chills, gastrointestinal disease, abdominal pain, epigastric discomfort, numbness, tremor, muscle rigidity, discomfort in the head, increased liver enzymes, worsening of liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, anxiety, insomnia, drowsiness, simplex herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, abdominal pain, heart failure, edema, worsening of liver disease, knee abnormalities, stroke, diabetic macular edema with decreased vision, fatal and non-fatal liver failure, weight gain, fracture, bladder cancer

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that does not allow light to enter. Additionally, avoid humid areas and store in a cool place between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

White to grayish-white round tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.